 STOCKHOLM and BAD VILBEL, Germany, July 21, 2021 PRNewswire -- Calliditas Therapeutics AB Nasdaq: CALT, Nasdaq Stockholm: CALTX Calliditas and STADA Arzneimittel AG STADA announced today that they have entered into a license agreement to register and commercialize a novel specialty drug candidate for the treatment of the chronic autoimmune kidney disease Immunoglobulin A Nephropathy IgAN in the European Economic Area EEA member states, Switzerland and the UK. Under the terms of the agreement, Calliditas is entitled receive an initial upfront payment of 20M EUR 24m upon signing and up to an additional 77.5M EUR 91m in future payments linked to pre-defined regulatory and commercialization milestones. 